Beam Therapeutics Inc - Asset Resilience Ratio
Beam Therapeutics Inc (BEAM) has an Asset Resilience Ratio of 67.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beam Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Beam Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BEAM current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Beam Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BEAM long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $933.10 Million | 67.31% |
| Total Liquid Assets | $933.10 Million | 67.31% |
Asset Resilience Insights
- Very High Liquidity: Beam Therapeutics Inc maintains exceptional liquid asset reserves at 67.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Beam Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Beam Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Beam Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Beam Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.16% | $950.27 Million | $1.48 Billion | +12.63pp |
| 2024-12-31 | 51.53% | $568.77 Million | $1.10 Billion | -0.13pp |
| 2023-12-31 | 51.65% | $753.98 Million | $1.46 Billion | -11.35pp |
| 2022-12-31 | 63.01% | $845.37 Million | $1.34 Billion | +35.49pp |
| 2021-12-31 | 27.51% | $405.65 Million | $1.47 Billion | -2.93pp |
| 2020-12-31 | 30.44% | $137.50 Million | $451.68 Million | -4.55pp |
| 2019-12-31 | 35.00% | $54.63 Million | $156.10 Million | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more